脱髓鞘和再鞘:一般原理。

Q3 Neuroscience
Jianqin Niu, Alexei Verkhratsky, Arthur Butt, Chenju Yi
{"title":"脱髓鞘和再鞘:一般原理。","authors":"Jianqin Niu, Alexei Verkhratsky, Arthur Butt, Chenju Yi","doi":"10.1007/978-3-031-87919-7_9","DOIUrl":null,"url":null,"abstract":"<p><p>Myelinating oligodendrocytes and oligodendrocyte precursor cells (OPCs) make up half the cells in the central nervous system and are affected by and contribute to all neurological diseases. The pathology of myelinating oligodendrocytes is fundamentally characterized by myelin disruption and loss, termed demyelination, whereas that of OPCs is principally defined by remyelination and repair in the form of regeneration of myelinating oligodendrocytes. Demyelination is generally associated with white matter diseases, such as multiple sclerosis, although oligodendroglial pathology is a major factor in most neuropathologies, including Alzheimer's disease, ischaemic injury, and traumatic injury. Oligodendroglial changes are often driven by neuroinflammatory factors and involve oxidative stress, metabolic malfunction, and excitotoxicity. Understanding the complexities of demyelination and remyelination pathogenesis is essential for the development of new therapeutic strategies. In this chapter, we summarise the key features of demyelination and remyelination, discuss factors underlying a remyelination failure, and compare the differences between humans and mice. We propose some perspectives on treatment strategies for remyelination in the hope that future advances will provide solutions to the challenges associated with demyelinating diseases.</p>","PeriodicalId":7360,"journal":{"name":"Advances in neurobiology","volume":"43 ","pages":"207-255"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Demyelination and Remyelination: General Principles.\",\"authors\":\"Jianqin Niu, Alexei Verkhratsky, Arthur Butt, Chenju Yi\",\"doi\":\"10.1007/978-3-031-87919-7_9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Myelinating oligodendrocytes and oligodendrocyte precursor cells (OPCs) make up half the cells in the central nervous system and are affected by and contribute to all neurological diseases. The pathology of myelinating oligodendrocytes is fundamentally characterized by myelin disruption and loss, termed demyelination, whereas that of OPCs is principally defined by remyelination and repair in the form of regeneration of myelinating oligodendrocytes. Demyelination is generally associated with white matter diseases, such as multiple sclerosis, although oligodendroglial pathology is a major factor in most neuropathologies, including Alzheimer's disease, ischaemic injury, and traumatic injury. Oligodendroglial changes are often driven by neuroinflammatory factors and involve oxidative stress, metabolic malfunction, and excitotoxicity. Understanding the complexities of demyelination and remyelination pathogenesis is essential for the development of new therapeutic strategies. In this chapter, we summarise the key features of demyelination and remyelination, discuss factors underlying a remyelination failure, and compare the differences between humans and mice. We propose some perspectives on treatment strategies for remyelination in the hope that future advances will provide solutions to the challenges associated with demyelinating diseases.</p>\",\"PeriodicalId\":7360,\"journal\":{\"name\":\"Advances in neurobiology\",\"volume\":\"43 \",\"pages\":\"207-255\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in neurobiology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/978-3-031-87919-7_9\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Neuroscience\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in neurobiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/978-3-031-87919-7_9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Neuroscience","Score":null,"Total":0}
引用次数: 0

摘要

髓鞘性少突胶质细胞和少突胶质细胞前体细胞(OPCs)占中枢神经系统细胞的一半,受所有神经系统疾病的影响并导致所有神经系统疾病。髓鞘少突胶质细胞的病理基本特征是髓鞘破坏和丢失,称为脱髓鞘,而OPCs的病理主要是髓鞘再生和修复,即髓鞘少突胶质细胞的再生。脱髓鞘通常与白质疾病有关,如多发性硬化症,尽管少突胶质病理是大多数神经病理的主要因素,包括阿尔茨海默病、缺血性损伤和创伤性损伤。少突胶质细胞的改变通常由神经炎症因子驱动,涉及氧化应激、代谢功能障碍和兴奋性毒性。了解脱髓鞘和再脱髓鞘发病机制的复杂性对于开发新的治疗策略至关重要。在本章中,我们总结了脱髓鞘和再生的主要特征,讨论了再生失败的潜在因素,并比较了人类和小鼠之间的差异。我们对脱髓鞘再生的治疗策略提出了一些观点,希望未来的进展将为脱髓鞘疾病相关的挑战提供解决方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Demyelination and Remyelination: General Principles.

Myelinating oligodendrocytes and oligodendrocyte precursor cells (OPCs) make up half the cells in the central nervous system and are affected by and contribute to all neurological diseases. The pathology of myelinating oligodendrocytes is fundamentally characterized by myelin disruption and loss, termed demyelination, whereas that of OPCs is principally defined by remyelination and repair in the form of regeneration of myelinating oligodendrocytes. Demyelination is generally associated with white matter diseases, such as multiple sclerosis, although oligodendroglial pathology is a major factor in most neuropathologies, including Alzheimer's disease, ischaemic injury, and traumatic injury. Oligodendroglial changes are often driven by neuroinflammatory factors and involve oxidative stress, metabolic malfunction, and excitotoxicity. Understanding the complexities of demyelination and remyelination pathogenesis is essential for the development of new therapeutic strategies. In this chapter, we summarise the key features of demyelination and remyelination, discuss factors underlying a remyelination failure, and compare the differences between humans and mice. We propose some perspectives on treatment strategies for remyelination in the hope that future advances will provide solutions to the challenges associated with demyelinating diseases.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Advances in neurobiology
Advances in neurobiology Neuroscience-Neurology
CiteScore
2.80
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信